A film based on the true story of a leukemia patient smuggling Indian generics has led Beijing to reiterate its intention to cut cancer drug prices.

Boehringer Ingelheim is expanding the $77 million contract biologics plant it opened last year in Shanghai.

After opening its new global headquarters in Tokyo, Takeda is seeking buyers for its old headquarters in Osaka to help fund its Shire takeover.

The FDA has issued a warning letter for a Sichuan Friendly Pharmaceutical plant at Neijiang, Sichuan.

Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.

Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.

Takeda investors worry about Shire's hemophilia products; Biocon's biosimilars plant clears the FDA; C-Bridge Capital invests $35 million in Nuance.

A Chinese API maker that was put on the FDA’s import alert list in March has now been given an FDA warning letter.